Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Cardiology

What Happens During a Brugada Provocation Test?

At a Glance

A Brugada provocation test uses IV medications like ajmaline or flecainide to temporarily stress your heart and reveal hidden electrical patterns on an ECG. It is carefully monitored in a hospital to safely confirm or rule out Brugada syndrome without causing pain.

In this answer

4 sections

01

How the Medications Work: Stressing the Sodium Channels

02

What Will I Actually Feel?

03

Step-by-Step: What to Expect During the Procedure

04

What Happens Next?

A Brugada syndrome provocation test (or “drug challenge”) is a highly controlled, closely monitored medical procedure designed to temporarily unmask a hidden Brugada pattern on your electrocardiogram (ECG) [1][2]. If your doctor suspects you have Brugada syndrome but your baseline ECG looks normal, they may use intravenous (IV) medications like ajmaline, flecainide, or procainamide to temporarily stress your heart’s electrical system [1][3]. While the idea of provoking the heart may sound intimidating, the test is performed step-by-step in a specialized clinical setting with continuous monitoring and strict emergency safety protocols in place [4][5].

How the Medications Work: Stressing the Sodium Channels

Your heart relies on tiny gateways called sodium channels to conduct the electrical signals that tell it to beat. In Brugada syndrome, there is often an underlying vulnerability that prevents these channels from functioning properly [6][7].

These provocation medications are sodium channel blockers [8]. When administered, they further reduce the flow of sodium in the heart [6]. In a person without Brugada syndrome, this slight reduction doesn’t significantly change the ECG. However, in someone with Brugada syndrome, this temporary stress alters the electrical current, causing a specific electrical wave pattern to appear on the monitor that confirms the disease: the diagnostic Type 1 “coved” Brugada pattern [9][8].

What Will I Actually Feel?

One of the most common sources of anxiety is wondering what the medication will feel like. Unlike a physical stress test where you run on a treadmill and your heart visibly pounds, this medication simply slows the electrical current at a microscopic level. The vast majority of patients feel absolutely normal during the infusion. You should not feel pain or a racing heart. The electrical changes happening on the screen are completely painless.

Step-by-Step: What to Expect During the Procedure

1. The Safety Setup and Preparation

Before the test, your doctor will review your current medications, as some may need to be temporarily stopped. Because the provocation medications can occasionally trigger abnormal heart rhythms, the test is always conducted in a specialized room (such as an electrophysiology lab or intensive care unit) fully equipped with resuscitation equipment [4][10].

  • An IV line will be placed in your arm or hand.
  • You will be connected to an ECG machine. To increase the chances of spotting the hidden electrical pattern, technicians will place some of the ECG stickers (leads) higher up on your chest than usual, specifically in the 2nd or 3rd intercostal spaces [1][11].
  • A specialized doctor (often an electrophysiologist) and trained nurses will be in the room with you, watching the monitor the entire time [1][12].

2. The Medication Infusion

The doctor will begin administering the medication slowly through your IV. Intravenous ajmaline is preferred in many countries because it acts very quickly, while procainamide or flecainide are often used in regions where ajmaline is unavailable (like the United States) [3].

  • The infusion typically happens gradually over a few minutes [3].
  • Throughout the entire process, your doctor will be staring closely at your live ECG monitor, looking for changes in real time [12].

3. The “Stop” Signals

The clinical team follows strict safety guidelines. They will stop the IV infusion immediately if any of the following occur [13]:

  • The diagnostic Type 1 Brugada pattern appears on the screen. This means the test is “positive” and no more drug is needed [14][8].
  • Your heart’s electrical waves (specifically the QRS complex) begin to widen too much (typically around a 30% increase), which is a sign the drug is working too strongly [13][14].
  • Any abnormal heart rhythms (arrhythmias) occur [14].
  • The maximum safe dose of the medication is reached without any changes. This means the test is “negative” [15].

4. Recovery and Observation

Once the infusion stops, you will remain on the monitor until the drug clears your system and your ECG returns to its normal baseline [12]. The observation time depends on the specific IV medication used:

  • Ajmaline wears off very quickly. The electrical changes usually disappear shortly after the infusion stops, meaning you may only need to be monitored for a short period (such as an hour or two) before you can go home [16].
  • IV Flecainide or Procainamide last longer in the body, requiring a longer observation period before you can safely leave [17][16].

In the highly uncommon event that the medication causes an unsafe heart rhythm, the clinical team is standing by and immediately ready [4]. They keep an antidote medication called isoproterenol (which increases heart rate and counteracts the sodium channel blockers) drawn up and on standby, and they can use a defibrillator to immediately return your heart to a normal rhythm if needed [18][19].

What Happens Next?

If the test is positive, your doctor will have a follow-up discussion with you about the results. A positive test confirms the diagnosis of Brugada syndrome, and your care team will then focus on risk stratification—determining if you need lifestyle changes, avoidance of certain medications, or the placement of an implantable cardioverter-defibrillator (ICD) to protect your heart long-term [20][4].

Common questions in this guide

What does a Brugada provocation test feel like?
The test is completely painless. The medication simply slows the electrical current in your heart at a microscopic level, so you should feel absolutely normal during the infusion without pain or a racing heart.
Why are medications like ajmaline or flecainide used for this test?
These medications are sodium channel blockers that briefly reduce the flow of sodium in your heart. In someone with Brugada syndrome, this temporary stress alters the electrical current enough to show the diagnostic Brugada pattern on an ECG monitor.
Is the Brugada drug challenge safe?
The procedure is highly controlled and performed in a specialized clinical setting with continuous monitoring. Your medical team will stop the medication immediately if the Brugada pattern appears, and they have emergency equipment and antidote medications on standby.
How long do I need to stay at the hospital after the test?
The observation time depends on the specific IV medication used. Ajmaline wears off quickly and usually requires a short observation time, while flecainide or procainamide last longer in the body and require you to be monitored for a longer period before going home.
What happens if my Brugada provocation test is positive?
A positive test confirms a diagnosis of Brugada syndrome. Your doctor will discuss the results with you and determine the best care plan, which may include lifestyle changes, avoiding certain medications, or getting an implantable cardioverter-defibrillator (ICD).

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific medication (ajmaline, flecainide, or procainamide) will be used for my test, and why was that chosen?
  2. 2.Will high precordial leads (2nd or 3rd intercostal space) be used during my ECG monitoring to increase the test's sensitivity?
  3. 3.What is the specific observation period required for me after the infusion ends, based on the drug being used?
  4. 4.Are there any medications or supplements I am currently taking that should be stopped before the challenge?
  5. 5.What are the specific 'stop' criteria your team uses (e.g., a certain percentage of QRS widening) to ensure the test remains safe?
  6. 6.If the test is positive, how quickly will we meet to discuss the results and next steps for my care plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Positive Brugada Gene With No Symptoms: What Is The Risk?Why Does Brugada Syndrome Cause Agonal Breathing at Night?What Dental Anesthesia is Safe for Brugada Syndrome?What Do Brugada ECG Type 1 and Type 2 Mean?Is Epicardial Ablation a Cure for Brugada Syndrome?Brugada Fainting vs Vasovagal Syncope: How to Tell?What to Do for a Fever With Brugada SyndromeCan a Heavy Meal Trigger a Brugada Syndrome Episode?Brugada Syndrome vs. SUNDS: Are They the Same?Can You Drink Alcohol With Brugada Syndrome?Can I Exercise With Brugada Syndrome? Safety GuideHow to Check Medication Safety Using BrugadaDrugs.orgIs Brugada Syndrome Hereditary? | Inciteful MedWhat Is a Molecular Autopsy for Brugada Syndrome?Why is Quinidine Used for Brugada Syndrome?How Is the Shanghai Score for Brugada Syndrome Calculated?What is a Brugada Phenocopy? ECG Pattern ExplainedWhen Is an ICD Required for Brugada Syndrome?

References

References (20)
  1. 1

    The Diagnostic Yield of Brugada Syndrome After Sudden Death With Normal Autopsy.

    Papadakis M, Papatheodorou E, Mellor G, et al.

    Journal of the American College of Cardiology 2018; (71(11)):1204-1214 doi:10.1016/j.jacc.2018.01.031.

    PMID: 29544603
  2. 2

    Diagnosis and management of Brugada Syndrome Unmasked by Flecainide challenge in a patient with unexplained ventricular fibrillation: a case report.

    Oh HJ, Cho H, Ko KY, et al.

    Oxford medical case reports 2026; (2026(1)):omaf301 doi:10.1093/omcr/omaf301.

    PMID: 41613391
  3. 3

    Comparison of Ajmaline and Procainamide Provocation Tests in the Diagnosis of Brugada Syndrome.

    Cheung CC, Mellor G, Deyell MW, et al.

    JACC. Clinical electrophysiology 2019; (5(4)):504-512 doi:10.1016/j.jacep.2019.01.026.

    PMID: 31000106
  4. 4

    Diagnosis of Brugada Syndrome With a Sodium-Channel-Blocker Test: Who Should Be Tested? Who Should Not?

    Viskin S, Chorin E, Rosso R, et al.

    Circulation 2024; (150(8)):642-650 doi:10.1161/CIRCULATIONAHA.124.069138.

    PMID: 39159224
  5. 5

    Value of the sodium-channel blocker challenge in Brugada syndrome.

    Therasse D, Sacher F, Babuty D, et al.

    International journal of cardiology 2017; (245()):178-180 doi:10.1016/j.ijcard.2017.05.099.

    PMID: 28784436
  6. 6

    Mechanism of the effects of sodium channel blockade on the arrhythmogenic substrate of Brugada syndrome.

    Nademanee K, Veerakul G, Nogami A, et al.

    Heart rhythm 2022; (19(3)):407-416 doi:10.1016/j.hrthm.2021.10.031.

    PMID: 34742919
  7. 7

    Normal interventricular differences in tissue architecture underlie right ventricular susceptibility to conduction abnormalities in a mouse model of Brugada syndrome.

    Kelly A, Salerno S, Connolly A, et al.

    Cardiovascular research 2018; (114(5)):724-736 doi:10.1093/cvr/cvx244.

    PMID: 29267949
  8. 8

    Brugada Syndrome: Progress in Diagnosis and Management.

    Pappone C, Santinelli V

    Arrhythmia & electrophysiology review 2019; (8(1)):13-18 doi:10.15420/aer.2018.73.2.

    PMID: 30918662
  9. 9

    Risk Stratification in Brugada Syndrome: The "Impossible" Made Possible?

    Wilde AAM, Postema PG

    Journal of the American College of Cardiology 2016; (67(12)):1441-1443 doi:10.1016/j.jacc.2016.02.010.

    PMID: 27012404
  10. 10

    Anaesthesia for patients with hereditary arrhythmias part I: Brugada syndrome.

    Levy D, Bigham C, Tomlinson D

    BJA education 2018; (18(6)):159-165 doi:10.1016/j.bjae.2018.03.004.

    PMID: 33456827
  11. 11

    Validation and clinical implications of higher intercostal space electrocardiography in the patient with Brugada syndrome in Taiwan (SADS-TW BrS registry).

    Tseng H, Kuo MY, Chu CC, et al.

    Journal of the Formosan Medical Association = Taiwan yi zhi 2025; (124(6)):508-513 doi:10.1016/j.jfma.2024.12.005.

    PMID: 39665937
  12. 12

    Lethal ventricular arrhythmia due to entrectinib-induced Brugada syndrome: a case report and literature review.

    Futamura K, Hase T, Tanaka A, et al.

    International cancer conference journal 2023; (12(4)):299-304 doi:10.1007/s13691-023-00620-y.

    PMID: 37577345
  13. 13

    Sodium-channel blocker challenge in the familial screening of Brugada syndrome: Safety and predictors of positivity.

    Therasse D, Sacher F, Petit B, et al.

    Heart rhythm 2017; (14(10)):1442-1448 doi:10.1016/j.hrthm.2017.06.031.

    PMID: 28666944
  14. 14

    Management of untreatable ventricular arrhythmias during pharmacologic challenges with sodium channel blockers for suspected Brugada syndrome.

    Poli S, Toniolo M, Maiani M, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2018; (20(2)):234-242 doi:10.1093/europace/eux092.

    PMID: 28521022
  15. 15

    Yield and Pitfalls of Ajmaline Testing in the Evaluation of Unexplained Cardiac Arrest and Sudden Unexplained Death: Single-Center Experience With 482 Families.

    Tadros R, Nannenberg EA, Lieve KV, et al.

    JACC. Clinical electrophysiology 2017; (3(12)):1400-1408 doi:10.1016/j.jacep.2017.04.005.

    PMID: 29759671
  16. 16

    Provocative testing using low dose oral flecainide for diagnosis of Brugada syndrome: a report of two cases.

    Amir M, Kabo P, Rahma I

    European heart journal. Case reports 2022; (6(12)):ytac460 doi:10.1093/ehjcr/ytac460.

    PMID: 36751482
  17. 17

    Low-dose oral flecainide provocation test for Brugada syndrome: a case series.

    Nguyen Thanh X, Ngoc Tran T, Nguyen Van T, et al.

    The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology 2025; (77(1)):91 doi:10.1186/s43044-025-00679-3.

    PMID: 41055814
  18. 18

    Screening, diagnosis and follow-up of Brugada syndrome in children: a Dutch expert consensus statement.

    Peltenburg PJ, Hoedemaekers YM, Clur SAB, et al.

    Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2023; (31(4)):133-137 doi:10.1007/s12471-022-01723-6.

    PMID: 36223066
  19. 19

    The diagnostic role of pharmacological provocation testing in cardiac electrophysiology: a clinical consensus statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, the ESC Working Group on Cardiovascular Pharmacotherapy, the Association of European Paediatric and Congenital Cardiology (AEPC), the Paediatric & Congenital Electrophysiology Society (PACES), the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS).

    Behr ER, Winkel BG, Ensam B, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2025; (27(4)) doi:10.1093/europace/euaf067.

    PMID: 40165484
  20. 20

    Use, misuse, and pitfalls of the drug challenge test in the diagnosis of the Brugada syndrome.

    Wilde AAM, Amin AS, Morita H, Tadros R

    European heart journal 2023; (44(27)):2427-2439 doi:10.1093/eurheartj/ehad295.

    PMID: 37345279

This page provides educational information about the Brugada syndrome provocation test. It does not replace professional medical advice, so please consult your cardiologist or electrophysiologist about your specific testing needs.

Get notified when new evidence is published on Brugada syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.